Latest Conference Articles

Expert Examines Conflicting Adjuvant RCC Results

Conflicting results from large adjuvant studies for renal cell carcinoma may have been caused by differences between the clinical trial designs, patient populations, and assessment criteria.

Dr. Plimack on Significance of CheckMate-025 Trial in RCC

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.

Dr. Geoffrey Sklar On Immunotherapy Advancements in Bladder Cancer

Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.

Expert Discusses Neoadjuvant Treatment Potential in Advanced RCC

Neoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.

Novel Targeted Agents in Development, But Will Compete With Immunotherapy in RCC

Toni K. Choueiri, MD, dives into the ongoing research with volitinib, the competing yet complementary roles of targeted agents and immunotherapy, and the most important steps to take with biomarker research in the field of renal cell carcinoma.

Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCC

Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

Urology Expert Speaks on Key Advancements, PSA Testing in Prostate Cancer

The life expectancy of patients with metastatic castrate-resistant prostate cancer has doubled in recent years thanks to a multitude of new therapies, and there are still many more advancements to come.

Dr. Richard Harris on Advancements on the Horizon in Prostate Cancer

Richard Harris, MD, of UroPartners, says there are many exciting advancements currently happening in the field of prostate cancer. Harris shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Dr. Gary Kirsh on This Exciting Phase in Prostate Cancer Care

Gary Kirsh, MD, President of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses this exciting phase in prostate cancer care. Kirsh shared his insights during an interview with OncLive at the 2016 LUGPA Annual Meeting.

Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC

Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

Fulvestrant Bests Anastrozole in Phase III Breast Cancer Study

First-line treatment with fulvestrant led to significantly better progression-free survival compared with anastrozole for patients with HR-positive advanced breast cancer.

Frontline Cabozantinib Bests Sunitinib in mRCC

Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma.

Adjuvant Sunitinib Extends DFS in High-Risk RCC

Adjuvant sunitinib prolonged disease-free survival by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell renal cell carcinoma.

Atezolizumab Significantly Extends Survival in NSCLC

Atezolizumab (Tecentriq) reduced the risk of death by 27% compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Ceritinib Establishes PFS Advantage in Second-Line ALK+ NSCLC

Progression-free survival was more than 3 times longer with ceritinib (Zykadia) than with chemotherapy, the current second-line standard, in patients with advanced ALK-positive non–small cell lung cancer who progressed after first-line crizotinib.

Second-Line Nivolumab Data in mUC Show Efficacy as FDA Considers Approval

Safety, efficacy, and biomarker results from the phase II CheckMate-275 trial of the PD-1 inhibitor nivolumab (Opdivo) that support FDA and European Medicines Agency applications were reported at the 2016 ESMO Congress.

Dr. Mirza on the Phase III NOVA Trial in Ovarian Cancer

Mansoor Raza Mirza, MD, chief oncologist, Rigshospitalet, Copenhagen University Hospital, discusses the results of the phase III NOVA trial during an interview at the 2016 ESMO Congress.

Dr. Braghiroli on Clinical Characteristics of NRAS-Mutant CRC

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses clinical characteristics and outcomes of patients with NRAS-mutant metastatic colorectal cancer (mCRC) during an interview at the 2016 ESMO Congress.

Frontline Pembrolizumab Data Is Practice Changing for NSCLC

Single-agent pembrolizumab improved overall and progression-free survival compared with doublet chemotherapy for untreated patients with advanced non–small cell lung cancer who expressed PD-L1 on ≥50% of cells.

Antibody-Drug Conjugate Active in Pretreated Ovarian Cancer

A fourth of patients with heavily pretreated advanced ovarian cancer achieved objective responses with novel antibody-drug conjugate targeting protein tyrosine kinase 7.

Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant Melanoma

Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the results of the phase III COMBI-v study in BRAF-mutant melanoma during an interview at the ESMO 2016 Congress.

Dr. Bruix on the Phase III RESORCE Trial in HCC

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the results of the phase III RESORCE trial in hepatocellular carcinoma (HCC) during an interview at the 2016 ESMO Congress.

Regorafenib Shows Clinical Benefit in Patients with HCC Who Progress on Sorafenib

The oral multikinase inhibitor regorafenib (Stivarga) has the potential to become the standard of care as second-line treatment in patients with previously treated hepatocellular carcinoma who are unsuitable for loco-regional therapy and have progressed on sorafenib.

Ribociclib Leads to Major PFS Increase in HR+ Metastatic Breast Cancer

Postmenopausal women with hormone receptor-positive metastatic breast cancer had significant slowing of disease progression with the addition of the investigational cyclin-dependent kinase 4/6 inhibitor ribociclib to endocrine therapy.

Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer

Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline BRCA-positive platinum-sensitive, recurrent ovarian cancer.

Adjuvant Ipilimumab Improves Survival in High-Risk Melanoma

Treatment with ipilimumab reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.

Dr. Llombart-Cussac on the CASCADE Study in Metastatic Breast Cancer

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the CASCADE study, which assessed declines in treatment efficacy over time in patients with metastatic breast cancer, during an interview at the 2016 ESMO Congress.

Dr. Bastholt on Lenvatinib in NSCLC

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer at the 2016 ESMO Congress.

High Response Rates With Rucaparib in Heavily Pretreated Ovarian Cancer

The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.